Oligonucleotide

Molecular Assemblies Announces the Appointment of Two Industry Leaders to Its Commercial-Technology Advisory Board

Retrieved on: 
Tuesday, February 13, 2024

"With the deep knowledge, wisdom, and experience commercializing transformative life science products, the CTAB enables Molecular Assemblies to identify emerging opportunities and trends in the life sciences industry that can be solved with our breakthrough nucleic acid-based products," said Larry Stambaugh, Board Chair of Molecular Assemblies.

Key Points: 
  • "With the deep knowledge, wisdom, and experience commercializing transformative life science products, the CTAB enables Molecular Assemblies to identify emerging opportunities and trends in the life sciences industry that can be solved with our breakthrough nucleic acid-based products," said Larry Stambaugh, Board Chair of Molecular Assemblies.
  • "Molecular Assemblies is helping accelerate the life science industry by removing one of the largest bottlenecks in R&D – the availability of long, pure, accurate oligonucleotides," said Todd C. Peterson, Ph.D., CTAB Chair and MAI Board Director.
  • He is currently Founder and Principal at GenApex Bio, a life sciences Board service and advisory practice.
  • His extensive experience includes leadership roles at Sigma-Aldrich and Genome Systems, where he made significant contributions to the genomics field.

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

Retrieved on: 
Friday, January 19, 2024

“We were pleased to present new in vivo data for our proprietary Axiomer RNA editing technology platform at the Deaminet 2024 meeting, demonstrating robust editing of ACTB in the liver of NHP, as well as functional protein data with the liver target ANGPTL3 in mice,” said Gerard Platenburg, Chief Scientific Officer of ProQR.

Key Points: 
  • “We were pleased to present new in vivo data for our proprietary Axiomer RNA editing technology platform at the Deaminet 2024 meeting, demonstrating robust editing of ACTB in the liver of NHP, as well as functional protein data with the liver target ANGPTL3 in mice,” said Gerard Platenburg, Chief Scientific Officer of ProQR.
  • “To date, we have generated robust in vitro and in vivo preclinical platform data across a range of liver and CNS targets.
  • Presentation of new data highlighting up to 70% editing efficiency of ACTB in liver of mice and NHPs at multiple timepoints.
  • These new preclinical platform data further highlight the potential of Axiomer EONs in preparation for clinical development and supporting discovery of potential new therapeutic applications.

Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio

Retrieved on: 
Thursday, January 18, 2024

AATD can lead to severe progressive lung disease, including emphysema and chronic obstructive pulmonary disease (COPD), and severe liver disease leading to inflammation, cirrhosis, and fibrosis.

Key Points: 
  • AATD can lead to severe progressive lung disease, including emphysema and chronic obstructive pulmonary disease (COPD), and severe liver disease leading to inflammation, cirrhosis, and fibrosis.
  • Korro’s proprietary RNA editing platform, OPERA™, integrates a deep understanding of adenosine deaminase acting on RNA (ADAR) enzymology with expertise in oligonucleotide chemistry, machine learning optimization of oligonucleotides and fit-for-purpose delivery.
  • CHORDs™, or Customized High-fidelity Oligonucleotides for RNA Deamination, are single-stranded, anti-sense oligonucleotides designed to have high target efficiency and specificity by leveraging the pillars of OPERA.
  • The replay is available for 30 days following the January 9, 2024 conclusion of the presentation.

QPS Significantly Enhances Mass Spectrometry Laboratory Capacity

Retrieved on: 
Wednesday, January 10, 2024

QPS Holdings, LLC (QPS), a global contract research organization (CRO) that provides discovery, preclinical, bioanalysis, clinical trials, and clinical research services, is rapidly expanding its mass spectrometry capacity, adding 13 LC-MS machines in just 15 months at their laboratories in Newark, Delaware (USA) and Groningen, The Netherlands (NL).

Key Points: 
  • QPS Holdings, LLC (QPS), a global contract research organization (CRO) that provides discovery, preclinical, bioanalysis, clinical trials, and clinical research services, is rapidly expanding its mass spectrometry capacity, adding 13 LC-MS machines in just 15 months at their laboratories in Newark, Delaware (USA) and Groningen, The Netherlands (NL).
  • View the full release here: https://www.businesswire.com/news/home/20240110198636/en/
    Zamas Lam, PhD, Global Head of Bioanalytical (Mass Spec) & Preclinical Development, QPS LLC.
  • (Photo: Business Wire)
    This expansion includes the impressive growth seen in 2023, when QPS installed seven additional UPLC-(HR)MS/MS tandem instruments - four triple quadrupoles, one QTRAP, and two quadrupole time-of-flight high-resolution mass spectrometers (HRMS).
  • QPS Subject Matter Experts are some of the best in the industry and this new equipment will provide the capacity for them to expand their relationships with our important biotech and pharmaceutical clients,” said Zamas Lam, PhD, Global Head of Bioanalytical (Mass Spec) & Preclinical Development, QPS LLC.

Oligonucleotide Synthesis Market to Exceed 9.9 billion by 2035 Say, Roots Analysis

Retrieved on: 
Wednesday, January 10, 2024

LONDON, Jan. 10, 2024 /PRNewswire/ -- The global oligonucleotide synthesis market is anticipated to be worth USD 3.5 billion in 2023, and it is expected to reach 9.9 billion by 2035. It is estimated to grow at a compounded annual growth rate (CAGR) of 16.1% during the forecast period (2023-2035).

Key Points: 
  • The oligonucleotide synthesis market faces several challenges, including the complexity of synthesis procedures, purification difficulties, gaps in analytical expertise, cost intensiveness, and regulatory constraints.
  • The growth factors for the oligonucleotide synthesis market include the expanding applications of oligonucleotides in genetic testing, diagnostics, and therapeutics.
  • Recent Developments in Oligonucleotide Synthesis Market:
    Several recent developments have taken place in the field of oligonucleotide synthesis.
  • FDF operation will dominate the oligonucleotide synthesis market during the forecast period and is anticipated to capture 53% of the market share in 2023.

Oligonucleotide Synthesis Market to Exceed 9.9 billion by 2035 Say, Roots Analysis

Retrieved on: 
Wednesday, January 10, 2024

LONDON, Jan. 10, 2024 /PRNewswire/ -- The global oligonucleotide synthesis market is anticipated to be worth USD 3.5 billion in 2023, and it is expected to reach 9.9 billion by 2035. It is estimated to grow at a compounded annual growth rate (CAGR) of 16.1% during the forecast period (2023-2035).

Key Points: 
  • The oligonucleotide synthesis market faces several challenges, including the complexity of synthesis procedures, purification difficulties, gaps in analytical expertise, cost intensiveness, and regulatory constraints.
  • The growth factors for the oligonucleotide synthesis market include the expanding applications of oligonucleotides in genetic testing, diagnostics, and therapeutics.
  • Recent Developments in Oligonucleotide Synthesis Market:
    Several recent developments have taken place in the field of oligonucleotide synthesis.
  • FDF operation will dominate the oligonucleotide synthesis market during the forecast period and is anticipated to capture 53% of the market share in 2023.

WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site

Retrieved on: 
Monday, January 8, 2024

SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, announced the commissioning of its two new peptide manufacturing plants, one at its Changzhou facility and another at the new Taixing site in China. This significant expansion has increased the company's Solid-Phase Peptide Synthesis (SPPS) total reactor volume to 32,000 liters, addressing the surging global demand for peptide therapeutics.

Key Points: 
  • The other newly commissioned peptide plant is situated at the company's Taixing site.
  • Commissioning the peptide plant at the Taixing site marks its official launch as the newest and largest of WuXi AppTec's five API production sites.
  • Dr. Minzhang Chen, Co-CEO of WuXi AppTec, commented: "The launch of our new peptide manufacturing plants and the development of the new Taixing site are important milestones for WuXi AppTec.
  • WuXi AppTec will continue to focus on enhancing our capability and capacity, accelerating innovative therapies to patients globally."

Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones

Retrieved on: 
Monday, January 8, 2024

We expect 2024 will be an inflection year that will drive significant value for Wave, our shareholders, and most importantly, for the patients who will benefit from our research,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences.

Key Points: 
  • We expect 2024 will be an inflection year that will drive significant value for Wave, our shareholders, and most importantly, for the patients who will benefit from our research,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences.
  • Expected milestones: Wave plans to deliver proof-of-mechanism data in individuals with AATD in 2024.
  • Expected milestones: Wave expects to deliver data, including dystrophin protein expression from muscle biopsies at 24 weeks, in the third quarter of 2024.
  • A live webcast of this presentation will be available on the Investor Relations page of the Wave Life Sciences website at http://ir.wavelifesciences.com .

Oligo Factory Announces GMP Compliance

Retrieved on: 
Wednesday, January 3, 2024

Oligo Factory, a leading manufacturer of high-quality oligonucleotides at scale, announces today that it is compliant with current Good Manufacturing Practices (GMP).

Key Points: 
  • Oligo Factory, a leading manufacturer of high-quality oligonucleotides at scale, announces today that it is compliant with current Good Manufacturing Practices (GMP).
  • Oligo Factory has implemented a comprehensive quality management system to align its operations with GMP guidelines.
  • I’m extremely proud of our team who worked tirelessly throughout 2023 to achieve this milestone," said Chris Boggess, CEO of Oligo Factory.
  • In early 2023, Oligo Factory opened a state-of-the-art oligonucleotide synthesis facility in Holliston, MA, to meet growing demand for its services.

Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides

Retrieved on: 
Wednesday, December 27, 2023

BEDMINSTER, N.J, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform technology, announces results from a series of in vivo studies demonstrating successful oral delivery of two LNC-formulated small single-strand oligonucleotides that specifically target key inflammatory cytokines TNFα and IL-17A in well-established and validated animal models that mimic acute inflammatory responses seen in human diseases.

Key Points: 
  • Commensurate improvements in clinical disease markers and scores were also documented in both models,” said James Ferguson, M.D., Matinas’ Chief Medical Officer .
  • “While additional study is warranted, the successful oral delivery of small oligonucleotides is very exciting and we believe these data demonstrate how Matinas’ LNC platform could be used for the oral delivery of functional small oligonucleotides with potential therapeutic applications,” Dr. Ferguson added.
  • Both were advanced to in vivo studies to evaluate meaningful biological activity in relevant disease models.
  • In this model, while IL-17A serum levels were not expected to change, improvement was demonstrated in clinical disease markers of skin redness and scaling, further validating the biological activity of these small oligonucleotides.